In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about a blood test that could predict cognitive decline before pathological signs, the use of tirofiban after tenecteplase for stroke, and the role of artificial intelligence in peer review.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about a pilot American Board of Psychiatry and Neurology Academic Pathway, a study of the EpiWatch app, and a new approach to magnetic resonance scanning.

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about asundexian reducing recurrent ischemic stroke, the link between the high-dose flu vaccine and Alzheimer's dementia incidence, and the evolving role of osteopathic medicine in neurology.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about appointment wait times for commercially insured patients, post-traumatic headache severity in children with a family history of migraine, and the FDA approval of a drug for Alzheimer's agitation.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a link between higher meat and slower cognitive decline in APOE34/44 carriers, the geographic distribution of research funding, and how artificial intelligence is reshaping neurology.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a new selective dopamine agonist for people with Parkinson's disease, the use of artificial intelligence in preparing journal manuscripts, and caffeinated coffee's role in reducing dementia risk.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the increase in neurology residency matches this year, the risk of dementia in people with Type 1 diabetes, and the role of neurologists in the public health conversation.

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the academic job market for fellowship graduates, the challenges of today's complex neuromuscular therapies, and the changes made in a new stroke guideline.